1 recruiting, 1 unknown. 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Intermediate-High Risk: new trials by email Literature Review of Intermediate-High Risk trials Research Report on Intermediate-High Risk
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL Orelabrutinib Combined with Pola-R-CHP Regimen - DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2026-08-30 | 2026-08-21 |
| Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism Sildenafil/apixaban, apixaban - Pulmonary Embolism, Intermediate-high Risk | Phase 1 | Unknown | Meshalkin Research Institute of Pathology of Circulation | 100 | 2016-10-01 | 2016-11-01 |
Dendritic Cell Sarcoma, Interdigitating (1) · Pulmonary Embolism (1)
Cardiovascular Diseases (1) · Embolism (1) · Embolism and Thrombosis (1) · Hemic and Lymphatic Diseases (1) · Histiocytic Disorders, Malignant (1) · Histiocytosis (1) · Lung Diseases (1) · Lymphatic Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Respiratory Tract Diseases (1) · Vascular Diseases (1)
Cyclophosphamide (1) · Doxorubicin (1) · Prednisone (1) · Rituximab (1) · Sildenafil Citrate (1) · apixaban (1) · orelabrutinib (1) · polatuzumab vedotin (1)
Meshalkin Research Institute of Pathology of Circulation (1) · The First Affiliated Hospital of Xiamen University (1)
China (1) · Russia (1)
Bing Xu, PhD，MD (1)